Thioredoxin Systems Overview
- Year Founded
-
1994
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$2.4M
- Investors
-
6
Thioredoxin Systems General Information
Description
Developer of pharmaceutical products designed for the treatment of multidrug-resistant infections. The company's technology utilizes a combination of silver ions and ebselen to disable bacterial thioredoxin enzyme systems, enabling healthcare providers to use a bactericidal antibiotic that treats urinary tract infections without triggering cross-resistance.
Contact Information
Website
www.txnsystems.comCorporate Office
- Nanna Svartz Väg 2
- Solna
- 171 65 Stockholm
- Sweden
Corporate Office
- Nanna Svartz Väg 2
- Solna
- 171 65 Stockholm
- Sweden
Thioredoxin Systems Timeline
Thioredoxin Systems Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 30-Oct-2024 | $2.4M | Completed | Generating Revenue | ||
| 1. Later Stage VC | 31-Dec-2022 | Completed | Startup |
Thioredoxin Systems Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Thioredoxin Systems Patents
Thioredoxin Systems Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10653717-B2 | Antibiotic compositions | Active | 05-Dec-2016 | ||
| US-11801262-B2 | Antibiotic compositions | Active | 05-Dec-2016 | ||
| US-20180185410-A1 | Antibiotic compositions | Active | 05-Dec-2016 | ||
| US-20200281967-A1 | Antibiotic compositions | Active | 05-Dec-2016 | ||
| AU-2017374015-A1 | Antibiotic compositions comprising silver and selenium | Active | 05-Dec-2016 | A61K33/04 |
Thioredoxin Systems Signals
Thioredoxin Systems Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Annexstruktur AB | Corporate Venture Capital | Minority | ||
| GOBIA Enterprises | Venture Capital | Minority | ||
| GU Ventures | Accelerator/Incubator | Minority | ||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority |
Thioredoxin Systems FAQs
-
When was Thioredoxin Systems founded?
Thioredoxin Systems was founded in 1994.
-
Where is Thioredoxin Systems headquartered?
Thioredoxin Systems is headquartered in Stockholm, Sweden.
-
What is the size of Thioredoxin Systems?
Thioredoxin Systems has 9 total employees.
-
What industry is Thioredoxin Systems in?
Thioredoxin Systems’s primary industry is Drug Discovery.
-
Is Thioredoxin Systems a private or public company?
Thioredoxin Systems is a Private company.
-
What is Thioredoxin Systems’s current revenue?
The current revenue for Thioredoxin Systems is .
-
How much funding has Thioredoxin Systems raised over time?
Thioredoxin Systems has raised $3.45M.
-
Who are Thioredoxin Systems’s investors?
Annexstruktur AB, GOBIA Enterprises, GU Ventures, , and are 5 of 6 investors who have invested in Thioredoxin Systems.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process